Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: Synthesis and biological activity.
Nitrogen-containing fused ring compounds and use thereof
申请人:Hirata Kazuyuki
公开号:US20070010670A1
公开(公告)日:2007-01-11
A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]:
wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.
Tetrahydroquinoline analogues as muscarinic agonists
申请人:Skjaerbaek Niels
公开号:US20050209226A1
公开(公告)日:2005-09-22
The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
This invention relates to a transition metal mediated process for the preparation of optionally substituted 2-amino-benzoxazoles and or 2-amino-benzimidazoles, which are useful as therapeutic agents or as intermediates in the synthesis of therapeutic agents.
AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR
申请人:SEIKA CORPORATION
公开号:US20180079732A1
公开(公告)日:2018-03-22
A novel asymmetric diamine, diamino-2-(benzothiazole-2-yl)diphenyl ether, derivatives therefor, and an intermediate for the compound such as aminonitro-2-(benzothiazole-2-yl)diphenyl ether, dinitro-2-(benzothiazole-2-yl)diphenyl ether, and derivatives from these. Additionally, another novel asymmetric diamine, diamino-2-(benzoxazole-2-yl)diphenyl ether, derivatives therefor, and intermediate for the compound such as aminonitro-2-(benzoxazole-2-yl)diphenyl ether, dinitro-2-(benzoxazole-2-yl)diphenyl ether, and derivatives from these, and methods for preparing them.
The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.